Table 1.
Characteristics of studies included in this meta-analysis.
| Author, year |
Phase | Pathology | Line | Treatment groups | No. of Patients | Median age, years | No. of younger (%) | No. of older (%) | Follow-up (months) | Overall survival | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall HR (95% CI) |
HR (95% CI) for younger | HR (95% CI) for older | ||||||||||
| Brahmer (2015) | 3 | NSCLC | >1 | Nivolumab vs Docetaxel | 272 | 63.0 (39-85) | 152 (56%) | 120 (44%) | 11.0 months† | 0.63 (0.48-0.82) | <65 yr: 0.62 (0.44-0.89) | A (≥65 and <75 yr): 0.51 (0.32-0.82) B (≥75 yr): 1.76 (0.77-4.05) |
|
| ||||||||||||
| Borghaei (2015) | 3 | NSCLC | >1 | Nivolumab vs Docetaxel | 582 | 62.0 (21-85) | 339 (58%) | 243 (42%) | 17.2 months | 0.75 (0.62-0.91) | <65 yr: 0.81 (0.62-1.04) | A (≥65 and <75 yr): 0.63 (0.45-0.89) B (≥75 yr): 0.90 (0.43-1.87) |
|
| ||||||||||||
| Herbst (2015) |
2/3 | NSCLC | >1 | Pembrolizumab (2 mg/kg) vs Pembrolizumab (10 mg/kg) vs Docetaxel |
1033 | 62.5 (54-70) | 604 (58%) | 429 (42%) | 13.1 months | 0.67 (0.56–0.80) | <65 yr: 0.63 (0.50-0.79) | ≥65 yr: 0.76 (0.57–1.02) |
|
| ||||||||||||
| Reck (2016) |
3 | SCLC | 1 | Ipilimumab + EP vs Placebo + EP | 954 | 62.5 (36-85) | 576 (60%) | 378 (40%) | 10.5 vs10.2 months | 0.94 (0.81-1.09) | <65 yr: 1.08 (0.90-1.31) | A (≥65 and <75 yr): 1.14 (0.87 to 1.49) B (≥75 yr): 0.70 (0.40 to 1.20) |
|
| ||||||||||||
| Carbone (2017) |
3 | NSCLC | 1 | Nivolumab vs Investigator's choice of platinum doublet chemotherapy | 541 | 64.0 (29-89) | 281 (52%) | 260 (48%) | 18.0 months | 1.08 (0.87–1.34) | <65 yr: 1.13 (0.83-1.54) | ≥65 yr: 1.04 (0.77–1.41) |
|
| ||||||||||||
| Govindan (2017) | 3 | NSCLC | 1 | Ipilimumab + PC vs Placebo +PC | 749 | 64.0 (28-85) | 380 (51%) | 369 (49%) | 12.5 vs 11.8 months | 0.91 (0.77–1.07) | <65 yr: 0.82 (0.64-1.04) | A (65 and ≤ 74 yr): 1.06 (0.81-1.37) B (≥75 yr): 0.85 (0.51-1.43) |
|
| ||||||||||||
| Gandhi (2018) |
3 | NSCLC | >1 | Pembrolizumab + Pemetrexed + PBC vs Placebo + Pemetrexed + PBC | 616 | 64.0(34-84) | 312 (51%) | 304 (49%) | 10.5 months | 0.49 (0.38–0.64) | <65 yr: 0.43 (0.31-0.61) | ≥65 yr: 0.64 (0.43–0.95) |
|
| ||||||||||||
| Paz-Ares (2018) | 3 | NSCLC | 1 | Pembrolizumab + ICC vs Placebo + ICC | 559 | 65.0 (29-88) | 254 (45%) | 305 (55%) | 7.8 months |
0.64 (0.49–0.85) | <65 yr: 0.52 (0.34-0.80) | ≥65 yr: 0.74 (0.51–1.07) |
|
| ||||||||||||
| Horn (2018) |
3 | SCLC | 1 | Atezolizumab + CE vs Placebo + CE | 403 | 64.0 (26–90) | 217 (54%) | 186 (46%) | 13.9 months | 0.70 (0.54–0.91) | <65 yr: 0.92 (0.64-1.32) | ≥65 yr: 0.53 (0.36–0.77) |
|
| ||||||||||||
| Antonia (2018) |
3 | NSCLC | >1 | Durvalumab vs Placebo | 713 | 64.0 (23-90) | 391 (55%) | 322 (45%) | 25.2 months | 0.68 (0.54-0.86) | <65 yr: 0.62 (0.44-0.86) | ≥65 yr: 0.76 (0.55–1.06) |
|
| ||||||||||||
| Barlesi (2018) |
3 | NSCLC | >1 | Avelumab vs Docetaxel | 529 | 63.5 (56-70) | 279 (53%) | 250 (47%) | 18.9 months | 0.90 (0.73–1.12) | <65 yr: 0.84 (0.63-1.13) | ≥65 yr: 0.98 (0.71–1.34) |
|
| ||||||||||||
| Fehrenbacher (2018) | 3 | NSCLC | >1 | Atezolizumab vs Docetaxel | 1225 | 63.5 (25-85) | 661 (54%) | 564 (46%) | 26.0 months | 0.80 (0.70-0.92) | <65 yr: 0.84 (0.79-1.01) | ≥65 yr: 0.75 (0.61-0.91) |
Abbreviations. NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer. †Represents minimum follow-up time between the start of the study (the first visit of the first enrolled patient) and the end of the study (the last visit of the last enrolled patient). EP=Etoposide plus Platinum. PC=Paclitaxel plus Carboplatin. PDC=Platinum doublet chemotherapy. PBC=Platinum-based chemotherapy. ICC= investigator's choice of chemotherapy. CE= Carboplatin plus Etoposide.